ALCAM and prostate carcinoma: Notably, cells treated with 30 μg/ml of BLE extract showed a significant reduction in the expression levels of Sox2, Oct4, Nanog, CD44 and CD166, all markers known to be expressed in prostate cancer stem cells, compared to control non-treated cells (Fig. S3).